News


still image of video, click to play.

On November 8, 2022, Dr. Ross Camidge, Dr. Misako Nagasaka and Janet Freeman-Daily, the ROS1ders co-founder discussed the current and future treatment landscape including taletrectinib for ROS1+ NSCLC.

still image of video, click to play.

On June 7, 2022, Dr. Wei Li, Dr. Caicun Zhou, Dr. Ross Camidge, and Dr. Misako Nagasaka discussed taletrectinib TRUST-I interim data in ROS1+ NSCLC patients as published at ASCO2022.

still image of video, click to play.

On June 3, 2023, Dr. David Reardon, Dr. Fabio Iwamato, and Dr. Nicole Willmarth discussed the current and future treatment landscape in IDH-mutant glioma.